Knight-Swift Transportation Holdings has seen its consensus analyst price target inch up to $53.25 from $52.21, signaling a slightly brighter outlook by Wall Street. This adjustment reflects a balance of new supply-side catalysts combined with persistent

Money markets have been flashing warnings for several weeks that the process, known as quantitative tightening, may have run its course. Now, Wall Street strategists say, stress signals have gathered such momentum that the Fed may be forced to end QT as

Procter Gamble’s sales grew in the first quarter and the consumer products company expects a milder effect from tariffs this fiscal year.

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu shots in the U.S.

() -Procter & Gamble on Friday beat Wall Street estimates for first-quarter revenue and profit, helped by strong demand for its beauty and hair-care products amid higher prices and a broader slowdown in spending due to economic uncertainties. The Tide mak

If Canada's Prime Minister Mark Carney has any frustrations he wants to share about his southern neighbor, he could do so with China's President Xi as soon as next week.

By Anna Szymanski LONDON (Reuters) -Everything Mike Dolan and the ROI team are excited to read, watch and listen to over the weekend. From the Editor Hello Morning Bid readers.

The Canadian government’s move follows the US automotive companies’ decision to scale-back manufacturing operations in the country.

While the idea of tariffs may be well intentioned, how have these tariffs actually affected American households? Experts explained.

Dyadic International's consensus analyst price target has recently been revised downward from $7.00 to $5.67 per share, reflecting a reassessment of the company's outlook. This change follows a modest increase in the discount rate from 6.94% to 7.04% as w

Apellis Pharmaceuticals recently announced new one-year results from the Phase 3 VALIANT study, highlighting sustained efficacy and favorable safety for EMPAVELI in treating rare kidney diseases, including C3 glomerulopathy and IC-MPGN. Notably, EMPAVELI

December S&P 500 E-Mini futures (ESZ25) are trending up +0.59% this morning as investors analyze the release of key U.S. inflation data for clues on the health of the economy and the Federal Reserve’s rate path.

In the first nine months this year, electric sales grew 1% from the same period in 2024 but were essentially flat on a weather-adjusted basis, said Jon Taylor, FirstEnergy chief financial officer. He anticipates “more meaningful” increases starting in the

As global markets navigate a mix of volatility and optimism, with U.S. stocks rebounding and central banks signaling further monetary easing, investors are increasingly focused on identifying opportunities amid the shifting economic landscape. In this env